Emcure Pharmaceuticals IPO: Will Namita Thapar from Shark Tank India Profit After Shares Listing?

Written by: Sarmeeli Mallick Updated Jul 1, 2024 | 08:10 PM IST

Emcure Pharmaceuticals IPO: Namita Thapar, known from Shark Tank India, bought shares in Emcure at an average cost of Rs 3.44 each.

Emcure Pharmaceuticals IPO: The initial public offering (IPO) of Emcure Pharmaceuticals will be open for public subscription from July 3 to July 5. So, how much will Namita Thapar, who is the Whole-time Director and part of the promoter group of the Pune-based pharmaceutical company, earn from this IPO?

Emcure Pharmaceuticals IPO Details

The IPO includes the issuance of new equity shares worth Rs 800 crore and an Offer For Sale (OFS) of 1.14 crore equity shares worth Rs 1,152 crore at the upper price band, by promoters and existing shareholders. This brings the total public offering size to Rs 1,952 crore.

Those selling shares in the OFS include promoter Satish Mehta and investor BC Investments IV Ltd, an affiliate of US-based private equity firm Bain Capital. Currently, Satish Mehta holds a 41.85% stake in the company, and BC Investments owns a 13.07% stake.

The company has set a price range of Rs 960 to Rs 1,008 per share for its Rs 1,952-crore IPO.

The money from the new share issue will be used to pay off debt and for general corporate purposes.

How much will Namita Thapar from Shark Tank India earn from Emcure Pharmaceuticals?

Namita Thapar, known from Shark Tank India, bought shares in Emcure at an average cost of Rs 3.44 each. She will sell about 12.68 lakh shares as part of the OFS in the IPO.

As of March 2024, she holds 63,39,800 equity shares, representing a 3.5% stake in Emcure Pharmaceuticals.

Considering the upper price band of Rs 1,008, Namita Thapar will earn around Rs 127 crore from selling her shares.

About Emcure Pharmaceuticals

Emcure Pharmaceuticals, based in Pune, develops, manufactures, and markets a wide range of pharmaceutical products globally across several major therapeutic areas.

In the IPO, up to 108,900 equity shares have been reserved for employees. Additionally, half of the issue size is reserved for qualified institutional investors (QIBs), 35% for retail investors, and the remaining 15% for non-institutional investors.

Investors can bid for a minimum of 14 shares and in multiples of 14 shares thereafter.

Kotak Mahindra Capital Company, Jefferies India, Axis Capital, and JP Morgan India are the lead managers for the issue. The company’s equity shares are expected to be listed on the BSE and NSE on July 10.

(With agency inputs)